Toxicities and Quality of Life with IO-IO Therapies in Patients with Advanced RCC
March 28th 2022Two oncologists describe common adverse events seen with IO-IO combination treatment regimens for advanced renal cell carcinoma, and how they interpret quality of life data from the CheckMate 214 trial.
Read More